Neurofibromatosis type 1
Introduction
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder characterized by tumorigenesis, pigmentary skin changes, and multisystem involvement. Historically known as von Recklinghausen disease after Friedrich Daniel von Recklinghausen. NF1 is included in a group of disorders known as neurocutaneous syndromes, or phakomatoses. The disorder exhibits huge clinical variability, even within affected families, and its manifestations evolve with age, underscoring the need for lifelong monitoring.
Genetics
The genetic basis of NF1 is pathogenic variants in the NF1 gene, located on chromosome locus 17q11.2. This gene encodes neurofibromin, that is a tumor suppressor protein that negatively regulates the RAS/MAPK (rat sarcoma/Mitogen-activated protein kinase) signaling pathway. This regulation occurs by acting as a GTPase-activating protein (GAP). Loss-of-function mutations increase RAS activity, promoting cellular proliferation and tumorigenesis.
The NF1 gene has a high mutation rate, and approximately 50% of cases arise from de novo mutations. This gene is large and complex, which contributes to the wide spectrum of mutations and phenotypic heterogeneity observed in affected individuals.
Epidemiology
Neurofibromatosis type 1 (NF1) is one of the most common single-gene disorders, alongside cystic fibrosis, sickle cell disease, and Duchenne muscular dystrophy, with an estimated prevalence of approximately 1 in 2,500–3,000 individuals worldwide. It affects males and females equally and occurs across all ethnic groups. The condition shows marked clinical variability, i.e., some individuals are only mildly affected, whereas others develop significant morbidity and may have a poorer prognosis. Advances in molecular diagnostics have improved detection rates, particularly in young children who present with subtle early features.
Pathophysiology
NF1 is a dysregulating disorder that impacts cell growth and differentiation. The absence or dysfunction of neurofibromin leads to constitutive activation of the RAS (rat sarcoma) pathway, resulting in increased cell proliferation, reduced apoptosis, and enhanced tumor cell genesis. Tumors in NF1, particularly neurofibromas, arise from Schwann cells but involve a complex microenvironment including fibroblasts, mast cells, and perineural cells. The disease also affects melanocyte function, explaining the characteristic pigmentary abnormalities, and can involve the vascular, skeletal, and central nervous systems.
Clinical manifestations
NF1 presents with a broad spectrum of clinical manifestations. The typical features include café-au-lait macules, axillary and inguinal freckling, and multiple neurofibromas. Plexiform neurofibromas (bag-of-worms) may cause significant morbidity due to their size and potential to transform into malignant peripheral nerve sheath tumors (MPNSTs). Ocular findings such as Lisch nodules (iris hamartomas) are highly diagnostic.
Neurological complications include learning disabilities, attention deficit/hyperactivity disorder, and seizures. An increased risk of tumors in various parts of the body, particularly of the optic pathway, is another important feature, as well as skeletal abnormalities such as scoliosis, tibial dysplasia, and pseudoarthrosis. Endocrine and vascular complications may occur, including hypertension due to renal artery stenosis or pheochromocytoma.
Diagnosis
Diagnosis of NF1 is primarily clinical and based on typical criteria, most recently updated by an international consensus panel. These criteria include the presence of sex or more, larger than 5 mm in diameter café-au-lait spots, neurofibromas, freckling in characteristic regions, optic glioma, Lisch nodules, distinctive osseous lesions, or a first-degree relative with NF1. Genetic analysis can confirm the diagnosis, particularly in cases where the diagnosis is uncertain or in young children with a positive family history who do not yet develop full clinical criteria. Molecular testing is also important for genetic counseling and prenatal diagnosis.
Treatment
Management of NF1 is multidisciplinary and focuses on surveillance, early detection of complications, and symptomatic treatment. There is no cure for the disorder. Regular clinical follow-up includes monitoring of growth, blood pressure, vision, neurological status, and skin findings. Imaging studies are performed when clinically indicated. Surgical intervention may be required for symptomatic or disfiguring neurofibromas, although recurrence is common. In recent years, targeted therapies such as MEK (mitogen-activated protein kinase) inhibitors (e.g., selumetinib) have shown efficacy in reducing the size of inoperable plexiform neurofibromas. Educational support and neuropsychological management are necessary for children with cognitive or behavioral difficulties.
Prognosis
The prognosis of NF1 is highly variable and depends on the severity and type of complications. Many individuals have a normal life expectancy with relatively mild manifestations, while others experience significant morbidity due to tumor size/location, neurological complications, or malignant transformation. The lifetime risk of developing malignant peripheral nerve sheath tumors is estimated at 8–13%, representing one of the most serious complications. Early diagnosis, regular surveillance, and advances in targeted therapies have improved outcomes, but NF1 remains a chronic, lifelong condition requiring ongoing medical care.
